The reiteration of a Buy rating and the maintenance of a $50 price target by a Benchmark analyst could positively influence investor sentiment and potentially lead to a short-term increase in the stock price of Halozyme Therapeutics. The analyst's endorsement serves as a reaffirmation of the company's value and prospects, which may be viewed favorably by the market.